Description:
Dovitinib (TKI258) potently inhibited FLT3, c-KIT, FGFR, VEGFR1/2/3, PDGFRß and CSF-1R with IC50 values of 1, 2, 5, 10, 8, 27, 36 nM respectively. Dovitinib selectively blocked the growth of wild-type (WT) or activated mutant FGFR3-transformed B9 cells and human myeloma cell lines. Dovitinib was an effective treatment in a xenograft mouse model of FGFR3 multiple myeloma.
- Molecular Weight:392.429
- Purity:> 95%
Molecular Formula:
C21H21FN6O
Appearance:
A crystalline solid
Synonyms:
Dovitinib, TKI258; TKI 258;TKI-258; CHIR 265; CHIR265; CHIR-265; RAF-265; RAF 265; RAF265. Weitere Informationen finden Sie
hier